10x Genomics director proposes sale of 4,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
10x Genomics, Inc. director Sarah Amalia Polonius-Teichmann filed notice of a proposed sale of 4,000 common shares, with an approximate sale date of November 20, 2026. The notice lists an aggregate market value of $223,080 and identifies the shares as restricted stock acquired from the issuer on February 21, 2026. It also lists August 21, 2026, in the field for the plan-adoption or instruction date if relying on Rule 10b5-1.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Restricted Stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What date is listed for the TXG Rule 10b5-1 plan or instruction?
AI-generated analysis. How Rhea-AI works. Not financial advice.